Leuphasyl

Leuphasyl is a synthetic pentapeptide (Tyr-D-Ala-Gly-Phe-Leu-OH) designed as an enkephalin receptor mimic for topical cosmetic applications, formulated as a claimed anti-wrinkle active ingredient based on the theoretical premise that modulation of enkephalin receptor activity at facial neuromuscular junctions could attenuate dynamic muscle contraction and reduce the appearance of expression lines. The proposed mechanism involves enkephalin receptor interaction to attenuate acetylcholine release or signal transmission at the dermal-epidermal neuromuscular interface, conceptually analogous to botulinum toxin in mechanism but operating at significantly lower potency through a distinct receptor pathway; this theoretical framework draws on the established pharmacology of endogenous enkephalins at opioid and related receptors.

expression line reduction, facial muscle relaxation, enkephalin pathway modulation.

Research on Leuphasyl primarily documents effects related to expression line reduction and facial muscle relaxation and enkephalin pathway modulation. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Leuphasyl, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

# Summary Research found that Leuphasyl and Vialox pentapeptides demonstrated distinct mechanisms for potential antiaging applications, with Leuphasyl showing stronger binding to MMP-13 (an enzyme involved in collagen breakdown) and Vialox preferentially targeting SIRT-1 (a cellular longevity regulator). This integrative study combining computational modeling and laboratory testing revealed both peptides exhibited favorable safety profiles and no cytotoxic effects on skin cells, suggesting potential as noninvasive dermocosmetic candidates.